Maternal RSV Vaccination Cuts Infant ICU Admissions by Half in First Year

UK Health Security Agency data from this week's annual RSV report points to a striking 50% reduction in intensive care admissions for infants under six months — the first full-year payoff of the NHS maternal vaccination programme rolled out in late 2024. For practitioners watching maternal immunisation evolve globally, this is the kind of clinical signal worth sitting with, because the mechanism is straightforward and the bedside impact is substantial.

What the numbers actually show

Across 20 NHS trusts participating in SARI Watch sentinel surveillance, the 2025–26 winter season logged 63 infants under six months admitted to ICU or HDU with confirmed RSV chest infection. The previous season, the same trusts reported 131 admissions. That 63-versus-131 comparison is where the 50% figure comes from — and it represents real babies who did not end up on a ventilator.

UKHSA noted that in previous seasons, well over 1,000 babies a week were brought to A&E with bronchiolitis through most of November and December, and the vast majority of those cases were RSV-driven. Last winter's peak weekly infant bronchiolitis A&E attendance was lower than in earlier years, and the peak season itself was shorter. Earlier work from UKHSA presented at the ESCMID conference had already shown that a maternal dose gives over 80% protection to the newborn against hospital admission; this annual report now confirms what that early signal meant at the bedside.

Why uptake still matters

Here is the line from the report I want every antenatal clinician to hear: only 61.7% of women giving birth between March 2025 and February 2026 had received the RSV vaccine. Roughly four in ten mothers — and therefore their infants — moved through labour without that protection. UKHSA's framing was plain about it: many thousands of babies remain at risk.

The programme offers vaccination from 28 weeks of pregnancy. UKHSA's guidance is that week 28 — or as soon after as possible — gives the best window for protecting even preterm babies, though the dose can be given right up until labour begins. The infants most likely to be admitted from RSV are those born in late summer or autumn, which means the third-trimester conversation carries enormous weight.

What to carry into the clinic room

Three patterns from this report translate directly into practice, regardless of which health system you sit inside:

• Vaccination timing. If RSV immunisation can be offered at the 28-week visit, offer it there. Delaying until a later appointment costs protection across the highest-risk delivery window.
• Seasonal awareness. The UK season peaked during weeks 49 to 52 last December. In settings where RSV circulates on a different calendar, the principle holds — match the intensity of your counselling to the months when infant exposure is highest.
• Mind the unprotected cohort. That "around 60% uptake" line is the real warning. The gap between eligible and vaccinated is precisely where severe illness concentrates.

The clinical takeaway is unhurried and clear: a single maternal dose, given at the right gestational window, is doing exactly what the early data promised. The remaining work is closing the cohort who are eligible but unvaccinated — and that conversation happens one antenatal visit at a time.